The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10651 malaria professionals are enjoying the free benefits of MalariaWorld today

atovaquone

The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against plasmodium falciparum

May 29, 2012 - 12:23 -- Kabogo Ndegwa
Author(s): 
Chotivanich K, Mungthin M, Ruengweerayuth R, Udomsangpetch R, Dondorp AM, Singhasivanon P, Pukrittayakamee S, White NJ
Reference: 
Malaria Journal 2012, 11:177 (28 May 2012)

MalariaWorldLipidaemia reduces the anti-malarial activity of lipophilic anti-malarial drugs.

Medical Condition: 
Medical Treatment: 

Open Access | Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stages

April 20, 2011 - 11:55 -- Kabogo Ndegwa
Author(s): 
Carlos Moneriz, Patricia Marin-Garcia, Andres Garcia-Granados, Jose M Bautista, Amalia Diez, Antonio Puyet
Reference: 
Malaria Journal 2011, 10:82 (10 April 2011)

MA displays anti-malarial activity at multiple intraerythrocytic stages of the parasite and, depending on the dose and incubation time, behaves as a plasmodial parasitostatic compound.

Medical Condition: 
Medical Treatment: 

Mitochondrial Electron Transport Inhibition and Viability of Intraerythrocytic Plasmodium falciparum

November 19, 2010 - 11:26 -- Kabogo Ndegwa
Author(s): 
Heather J. Painter, Joanne M. Morrisey, and Akhil B. Vaidya
Reference: 
Antimicrobial Agents and Chemotherapy, December 2010, p. 5281-5287, Vol. 54, No. 12

Although mitochondrial electron transport is a validated target of the antimalarial drug atovaquone, the molecular details underlying parasite demise are unclear.

Medical Condition: 
Medical Treatment: 

Discovery of Potent Small-Molecule Inhibitors of Multidrug-Resistant Plasmodium falciparum Using a Novel Miniaturized High-Throughput Luciferase-Based Assay

August 18, 2010 - 13:09 -- Kabogo Ndegwa
Author(s): 
Edinson Lucumi, Claire Darling, Doron C. Greenbaum, et al
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3597-3604, Vol. 54, No. 9

Malaria is a global health problem that causes significant mortality and morbidity, with more than 1 million deaths per year caused by Plasmodium falciparum. Most antimalarial drugs face decreased efficacy due to the emergence of resistant parasites, which necessitates the discovery of new drugs.

Medical Treatment: 

Open Access | Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene

May 24, 2010 - 13:18 -- Kabogo Ndegwa
Author(s): 
Afonso A, Neto Z, Castro H, Lopes D, Alves AC, Tomas AM, Rosario VD
Reference: 
Malaria Journal 2010, 9:135 (21 May 2010)

A mutation was found on the P. chabaudi cytb gene from the AS-ATQ sample a substitution at the residue Tyr268 for an Asn, this mutation is homologous to the one found in P. falciparum isolates resistant to ATQ.

Medical Treatment: 

Open Access | Methodology: Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt polymerase chain reaction

May 24, 2010 - 13:02 -- Kabogo Ndegwa
Author(s): 
Gan L, Loh J
Reference: 
Malaria Journal 2010, 9:134 (21 May 2010)

PCR-HRM is an inexpensive option for the determination of drug resistance profile in P. falciparum and will see increasing use as an alternative to sequencing and 5'nuclease PCR assays in reference laboratories or once PCR systems that are able to conduct HRM become commonplace.

Technology: 
Medical Treatment: 
Subscribe to RSS - atovaquone